Trialbee

"We Find Patients. You Find Cures."

Trialbee's Honey Platform™ is a vendor-agnostic, cloud-based SaaS that centralizes and standardizes patient recruitment activities from every source, channel, and partner—from initial interest through enrollment [1]. It delivers pre-qualified, trial-ready patients using behavioral insights and real-time eligibility checks, backed by live medical secondary screening to ensure only qualified referrals reach sites [2]. The platform provides unprecedented transparency and actionable insights for real-time patient tracking, higher-quality referrals that reduce site burden, and robust ROI reporting [1].

Where it wins

• Quality over Quantity: Live medical secondary screening of every web form submission ensures only pre-qualified referrals are sent to sites, achieving a 30% referral-to-consent ratio—double the industry average [2].
• Global Scale with Local Insight: Operates across 50 countries and 66 languages, leveraging a curated omnichannel network and dedicated digital marketing team to engage patients where they feel most comfortable [2].
• Real-Time Analytics: Provides live analytics of all recruitment progress, allowing sponsors and sites to optimize recruitment in real time and make smarter, faster decisions [2].

Credibility: The Honey Platform's efficacy is demonstrated by over 1.6 million online pre-screeners completed since 2021 and a 30% referral-to-consent ratio, double the industry average [2].

• SaaS Platform Delivery: The core product is the Honey Platform™, a cloud-based SaaS that centralizes and standardizes recruitment activities, enabling scalable delivery to global sponsors and sites [1].
• Hybrid Service Model: Combines technology with human expertise, including a dedicated digital marketing team and live medical secondary screening, to ensure high-quality referrals [2].
• Omnichannel Network: Leverages a curated network of partners and digital channels to reach patients across 50 countries and 66 languages, scaling outreach without proportional cost increases [2].
• Margin Focus: High-margin SaaS licensing is complemented by service fees for specialized recruitment and screening, with the platform driving efficiency and reducing site burden [1].

• SubjectWell: A patient recruitment marketplace connecting trials with participants; Trialbee differentiates with its vendor-agnostic Honey Platform and live secondary screening [3].
• Antidote: Provides patient recruitment services and a Match search engine; Trialbee competes with its global scale (50 countries) and higher referral-to-consent ratio [2][3].
• Evidation: Focuses on real-world health data insights; Trialbee differentiates with direct patient recruitment and behavioral insights for trial-ready patients [4].
• myTomorrows: Provides access to drugs in development for patients; Trialbee competes by focusing on pre-qualified referrals and site burden reduction [4].
• Differentiators: Trialbee's key differentiators are its 30% referral-to-consent ratio (double the industry average), live medical secondary screening, and the vendor-agnostic Honey Platform™ that centralizes recruitment activities [2].

• Slow Enrollment Timelines: 80% of clinical trials miss enrollment targets, leading to delayed drug development and increased costs [2].
• Low Referral-to-Consent Rates: Traditional recruitment methods result in high disqualification rates, with 78% of patients disqualified through secondary screening [2].
• Site Burden: Investigator sites spend significant time on secondary screening and managing disqualified referrals, reducing their capacity for patient care [2].
• Lack of Transparency: Sponsors and sites lack real-time visibility into recruitment progress, making it difficult to optimize efforts and ensure ROI [2].

Trialbee's acquisition by Varsity Healthcare Partners in January 2026 positions it for accelerated growth, leveraging private equity resources to expand its global footprint and AI capabilities [4]. The 30% referral-to-consent ratio is a significant competitive advantage, but scaling live secondary screening across 50 countries may strain operational margins. The integration of AI, such as the Scout chatbot, presents an opportunity to further automate patient matching and reduce costs, but regulatory scrutiny in healthcare AI could pose risks. The main risk is competition from well-funded players like Evidation and myTomorrows, which could erode market share if Trialbee fails to differentiate on quality and transparency. The next signal to watch is the adoption rate of the Honey Platform™ by top-tier CROs, which would validate its vendor-agnostic model and drive recurring revenue growth.

Trialbee should expand its AI-driven capabilities beyond the Scout chatbot to include predictive analytics for patient dropout rates, addressing a key pain point for sponsors and sites. The company should pursue strategic partnerships with electronic health record (EHR) providers to enable direct patient identification and referral, reducing reliance on external omnichannel networks. Trialbee should develop a tiered pricing model for the Honey Platform™, including a freemium option for smaller sites, to drive adoption and expand its customer base. The company should invest in regulatory compliance and data privacy certifications (e.g., HIPAA, GDPR) to build trust with sponsors in highly regulated markets like the EU and US.